Value in Health
1) panel on use of insulin of animal origin and its place in the treatment of Type 1 diabetes mellitus; 2) public forum on selective Cox-2 inhibitor NSAIDS; 3) focused consultation with patient safety groups to discuss risk minimization options regarding acetaminophen overdose and liver injury.
Canadian Examples of Patient Involvement
Patient Involvement Pilot Project (2014)  Explored the value and feasibility of patient involvement in the orphan drug context as starting point for systematic, structured opportunities to inform benefit-risk assessment and management  Simulated how input from patients, their caregivers, healthcare professionals and patient groups could be collected and incorporated in the drug submission review process.  Online questionnaires were designed to gather qualitative information on the following (examples of one biologic and one pharmaceutical):
-the impact on individual patient's quality of life; -experience with currently available therapies; -unmet medical need; and -the patient's level of risk tolerance
Results from the Pilot Project:  Patient education on regulatory review and decision-making processes and reviewer training on when and how to best consider patient input in these processes is needed;  Timing of when reviewers receive patient input is important;  Additional experience needed. 
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Opportunities and Future Prospects
Assessment of benefits and risks
• In Europe marketing approval is granted by The European Medicines Agency (EMA), a decentralized agency of the European Union (EU).
-Most approvals are valid EUwide. -National regulatory authorities are not included in the approval process unless they are the 'rapporteur' doing the evaluation.
• Added value of including patients' perspectives within EMA benefit-risk assessments has been widely discussed. 
Conclusion and Dissemination
 results and consensus from the benefit-risk assessment are communicated to a wider audience 
NICE: Social Value Judgements
 NICE has explicitly defined information by the type, format, and sources of evidence in its guidelines for assessment and testing of eligibility (appraisal).
 Appraisal is usually based on evidence from patients with a condition.
 Citizens characterise an overall societal perspective on what should be taken into account in decisionmaking related to distributive justice.
 Views of citizens' conferences are published in "Social Value Judgements".
Future Prospects
 Range of participation efforts on European level extends from qualitative surveys of patients' needs to approaches of science-based documentation of quantitative patient preferences.
 European pilot projects have shown that modeling of the benefit-risk assessment for medicines is possible.
 More research projects are needed to design the tools that are accessible to patients and other stakeholders, appropriate to the needs of the regulators/ assessors and that can be integrated into the current processes in benefit-risk evaluation. CDRH-sponsored study cited as an example that "followed many of the recommendations listed."
Regulatory Impact of the Study
 Used study's decision aid tool to evaluate EnteroMedics's Maestro Rechargeable System  Device failed to meet its co-primary trial endpoints 
Challenges
 When is it in society's best interest to approve novel health technologies that offer promising therapeutic benefits, but also have worrisome side effects?
 CDER: how to integrate qualitative data from public meetings into existing evidence-based decision making 
When is Patient Preference Information Potentially Valuable in Regulatory Review?
• Factors related to the patient perspective − Patients willing to accept a different degree of risk than regulators − Important differences in the preferences of subgroups of patients − Understanding the clinical experience requires considerable familiarity with the disease (e.g. highly subjective endpoints, lifestyle indication, rare diseases)
• Factors related to benefit-risk tradeoffs − Clear benefit with rare serious risks compared to alternatives − Modest benefit but considerably less risk than alternatives − Harms occur early/benefits occur later (e.g. Tx to delay disease onset) − Considerable uncertainty on whether a patient will realize the benefit or risks
• Factors related to novelty 
